VC
DRUG

Vivo Capital’s Bright Minds Biosciences DRUG Stock Holding History

Vivo Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1M Hold
557,172
– – 3.57% 8
2026
Q1 		$40.7M Buy
557,172
+55,555
+11% +$4.47M 3.38% 10
2025
Q4 		$39.1M Hold
501,617
– – 2.53% 13
2025
Q3 		$30.4M Buy
501,617
+250,045
+99% +$9.71M 2.45% 14
2025
Q2 		$6.57M Hold
251,572
– – 0.67% 30
2025
Q1 		$9.07M Hold
251,572
– – 1.2% 18
2024
Q4 		$9.06M Buy
+251,572
New +$8.85M 1.02% 22

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vivo Capital's DRUG Position: Q2 2026 in Review

Vivo Capital held its Bright Minds Biosciences (DRUG) position steady in Q2 2026 at 557,172 shares worth $39.1M. The position accounts for 3.57% of the portfolio, ranked #8.

Vivo Capital first reported a position in DRUG in Q4 2024 and has held it in 7 quarters since. The position peaked at $40.7M in Q1 2026. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Vivo Capital held 557,172 shares of Bright Minds Biosciences worth $39.1M as of Q2 2026.
  • Vivo Capital left its Bright Minds Biosciences share count unchanged in Q2 2026.
  • Bright Minds Biosciences made up 3.57% of Vivo Capital's portfolio in Q2 2026, its #8 holding.
  • Vivo Capital first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Vivo Capital's Bright Minds Biosciences position peaked at $40.7M in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.